Mabion S.A. (MAB) - Total Assets
Based on the latest financial reports, Mabion S.A. (MAB) holds total assets worth zł120.46 Million PLN (≈ $33.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Mabion S.A. shareholders equity for net asset value and shareholders' equity analysis.
Mabion S.A. - Total Assets Trend (2009–2024)
This chart illustrates how Mabion S.A.'s total assets have evolved over time, based on quarterly financial data.
Mabion S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Mabion S.A.'s total assets of zł120.46 Million consist of 28.8% current assets and 71.2% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 24.1% |
| Accounts Receivable | zł2.87 Million | 1.8% |
| Inventory | zł2.70 Million | 1.7% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł264.00K | 0.2% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Mabion S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Mabion S.A..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mabion S.A.'s current assets represent 28.8% of total assets in 2024, a decrease from 59.4% in 2009.
- Cash Position: Cash and equivalents constituted 24.1% of total assets in 2024, up from 1.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 1.8% of total assets.
Mabion S.A. Competitors by Total Assets
Key competitors of Mabion S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Mabion S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 1.45 | 0.13 |
| Quick Ratio | 0.23 | 1.26 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł-30.36 Million | zł18.38 Million | zł-80.21 Million |
Mabion S.A. - Advanced Valuation Insights
This section examines the relationship between Mabion S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -23.4% |
| Total Assets | zł159.47 Million |
| Market Capitalization | $33.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mabion S.A.'s assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mabion S.A.'s assets decreased by 23.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mabion S.A. (2009–2024)
The table below shows the annual total assets of Mabion S.A. from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł159.47 Million ≈ $43.89 Million |
-23.42% |
| 2023-12-31 | zł208.25 Million ≈ $57.31 Million |
+11.86% |
| 2022-12-31 | zł186.18 Million ≈ $51.24 Million |
+1.05% |
| 2021-12-31 | zł184.24 Million ≈ $50.70 Million |
+135.23% |
| 2020-12-31 | zł78.32 Million ≈ $21.56 Million |
-31.02% |
| 2019-12-31 | zł113.55 Million ≈ $31.25 Million |
-21.54% |
| 2018-12-31 | zł144.72 Million ≈ $39.83 Million |
+75.53% |
| 2017-12-31 | zł82.44 Million ≈ $22.69 Million |
-9.65% |
| 2016-12-31 | zł91.25 Million ≈ $25.11 Million |
-52.86% |
| 2015-12-31 | zł193.55 Million ≈ $53.27 Million |
-86.93% |
| 2014-12-31 | zł1.48 Billion ≈ $407.64 Million |
+96.26% |
| 2013-12-31 | zł754.68 Million ≈ $207.70 Million |
-80.97% |
| 2012-12-31 | zł3.97 Billion ≈ $1.09 Billion |
+14620.07% |
| 2011-12-31 | zł26.94 Million ≈ $7.41 Million |
+14.95% |
| 2010-12-31 | zł23.44 Million ≈ $6.45 Million |
+6632.39% |
| 2009-12-31 | zł348.15K ≈ $95.82K |
-- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more